MedTrace Logo

Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)

NCT06919991 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2025-11-13

No results posted yet for this study

Summary

The purpose of the study is to assess the effects of multiple doses of itraconazole (a strong CYP3A4 inhibitor) on single dose PK of casdatifan in healthy adults and to assess the effects of multiple doses of phenytoin (a strong CYP3A4 inducer) on single dose PK of casdatifan in healthy adults.

Conditions

  • Healthy Participants

Interventions

DRUG

Casdatifan

Administered as a single dose in treatment Periods 1, 2, and 3

DRUG

Itraconazole

Administered as multiple doses in treatment Period 2

DRUG

Phenytoin

Administered as multiple doses in treatment Period 3

Sponsors & Collaborators

  • Arcus Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Arcus Biosciences

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-02
Primary Completion
2025-10-18
Completion
2025-10-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06919991 on ClinicalTrials.gov